OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-11-30-accounts

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

Registered number: 01635916 Charity number: 284881

PENNY BROHN CANCER CARE

TRUSTEES' REPORT AND

FINANCIAL STATEMENTS FOR

THE YEAR ENDED

30 NOVEMBER 2025

1

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

CONTENTS PAGE
Reference and Administrative Details of the Charity, its Trustees and Advisers 3
Independent Auditor’s Report on the Financial Statements 16
Consolidated Statement of Financial Activities 19
Charity Statement of Financial Activities 20
Consolidated Balance Sheet 21
Charity Balance Sheet 21
Consolidated Statement of Cash Flows 22
Notes to the Financial Statements 23

2

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS

Trustees

Amanda Hill[, 3, 4 & 5] Bina Shah[2 & 4] Bronwen Wright[2] Charles Russell-Smith[1 & 3] Emma Wallis[ 1 & ,2] Harvey Marcus[,1 & 5,] Jacqueline Graves[2 & 4 ] (Retired March 2026) Jayne Tucker[1] Jessica Brohn[ 3, 4 & 5] Jonathan Green[1 & 5] Kate Pavli[2 & 4] Nicola Newton[ 2, 4 & 5,] Stephen Rosser[1 & 3]

Sub-committees

  1. Finance and Audit Committee,

  2. People, Culture and Inclusion Committee,

  3. Commercial Committee

  4. Services Committee

  5. Fundraising and Marketing Committee

Company Registered Number 01635916

Charity Registered Number 284881 Registered Office Chapel Pill Lane, Pill, Bristol, BS20 0HH Company Secretary Lisa Day (resigned 16.05.2025) Eleanor Davies (appointed 16.05.2025)

Chief Executive Officer Andrew Hufford Independent Auditors Burton Sweet Limited The Clock Tower 5 Farleigh Court Old Weston Road Flax Bourton Bristol BS48 1UR

“We need more than medicine to live well with cancer. We need to care for our mind, emotions, spirit, heart and soul.”

Penny Brohn, 1980

3

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

Chair’s foreword

It is my privilege to introduce Penny Brohn Cancer Care’s annual report and accounts for 2025. Our new Securing the Future strategic framework has been the lens for this year’s work, setting a clear course: reach more people earlier, sustain our future through disciplined planning and diversified income, and empower our people to deliver with confidence and care.

We made steady progress. We supported about 2,400 people directly at Penny Brohn Cancer Care and about 2,800 patients through our integrative cancer care partnership with GenesisCare. Across both points of access there were about 21,500 sessions attended. These numbers matter because they reflect practical help when it is needed most, delivered in ways that are accessible, consistent and of high quality.

Stability underpins impact. Early in the year we appointed a new Head of Fundraising and Communications and reshaped our approach to be more strategic, data informed and focused on engagement and growth. We invested in strategy, systems, orderly planning and insight, which was essential to our financial recovery plan and to signalling stability and momentum. I am pleased to report a year on year turnaround of about £400,000, moving from an operating deficit in 2024 to a modest operating surplus in 2025. We also took practical steps that make access easier and support income generation: integrating a new online booking platform, beginning a website rebuild to make it simpler for people to find and book support, strengthening our brand reach, and improving the client experience and capacity at Ham Green House.

Our people and volunteers remained central to everything. We brought fundraising and communications together under single leadership, and within Services introduced a Psychological and Emotional Support Lead role to strengthen that part of our offer. Headcount remained steady, supported by flexibly contracted colleagues whose hours helped us match resources to demand at Ham Green House and through our partnership delivery. Volunteers contributed an average of 500 hours each month, a meaningful increase on last year, and we were pleased to open up practical work experience to local students. These steps reflect our values of courage, resilience, compassion, warmth and community, and they point to the kind of organisation we want to be.

Looking ahead, the priorities in Securing the Future remain clear. We will extend our reach to more, and more diverse, people as early as possible. We will focus on support that delivers the greatest gains in quality of life, and we will continue to explain our impact plainly and act on what the evidence tells us. We will sustain our future through careful stewardship, strong partnerships and a consistent experience for the people we serve.

This is my final annual report and accounts as Chair. I came to Penny Brohn Cancer Care first as a husband, grateful for the support my wife received and the difference it made. I then did what many supporters do and took part in challenge events before joining the Board and, in time, becoming Chair. It has been a privilege to serve alongside our trustees, staff, volunteers, partners and supporters. My hope is that I leave the charity steadier than I found it, with a clear strategy, a strong team and a firm platform for growth. Thank you for your trust, your generosity and your commitment to this purpose. I am confident that Penny Brohn Cancer Care is well placed to secure the future and to help many more people live as well as possible with and beyond cancer.

Stephen Rosser Chair of Trustees

4

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

2025 year in review

1. Who we reached

In 2025 we supported 5,213 people. Of these 2,374 people were supported directly at Penny Brohn Cancer Care, an 11% year on year increase, and welcomed a record 1,950 first time registrations. Alongside this, we supported 2,839 patients during treatment through our integrative care partnership with GenesisCare. Across both points of access there were 21,376 sessions attended: 10,900 sessions attended directly at Penny Brohn Cancer Care and 10,476 sessions attended via the GenesisCare partnership.

Headlines

Note: Headline figures are rounded for readability. Exact figures are shown in the body text.

2. How we delivered support

Online

Online remained the main point of access for most people using Penny Brohn Cancer Care’s services directly, especially for those managing fatigue, distance, cost or health vulnerability. We recorded 8,886 sessions attended by 1,767 unique clients across Tai Chi, Relaxation Room, Breathwork, Clinical Hypnotherapy, Yoga, Nutrition, Strength and Stamina, Mindfulness, Qigong, Pilates and our four-week Treatment Support Programme. A mid-year snapshot survey found people value the consistency, connection and practical coping skills online support provides.

In person at Ham Green House

We delivered a full in person programme for 360 clients, including 6 residential retreats, 10 Wellbeing Days, 27 Create & Unwind sessions, 58 Nordic Walking groups, 9 Nutrition Café sessions, 9 Community Kitchen sessions and 21 Tea and Chat groups. Personalised one to one support remained central, with 24 Personal Planning sessions, 4 Doctor consultations, 1 Nutrition session, 70 Counselling sessions and 85 Scar Care sessions. Personal Planning was fully booked throughout the year.

GenesisCare

As a point of access to the same whole-person support, the GenesisCare pathway enabled our wellbeing consultants to reach 2,839 people during treatment, both online and in person.

5

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

3. Rebuilding for sustainable growth

The Strategic Leadership Team produced a revitalised three-year strategic framework to reach more people and open new avenues for growth, so that services and fundraising priorities could align to a clear direction of travel. We appointed a new Head of Fundraising and Communications to establish a more strategic, data-informed and engagement- and growth-focused model. That meant investing time in strategy, systems, order, reviews and data insights, which was essential to Penny Brohn Cancer Care’s financial recovery plan and to signalling stability and momentum. We achieved about £466,000 year on year turnaround, representing a 138% improvement on our 2024 result. This was achieved in part through a significant growth in hospitality income as we diversify income to realise future sustainable growth.

Highlights

Brand, digital and place

The difference we made

People reported meaningful gains in confidence, control and coping, with strong satisfaction across the programme.

6

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

“Overall fantastic. It has positively changed the direction of my cancer journey.”

“Online services were a lifeline. I felt less alone and more supported.”

Thank you: To everyone who chose to support Penny Brohn UK in 2025 through gifts, grants, partnerships, practical help and quiet encouragement, thank you. Your trust in our work helps us keep serving people affected by cancer with care, skill and compassion.

7

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

We would additionally like to thank:

Bailey of Bristol, BDO UK (Bristol), Craddys, Grace Trust, Kent Community Foundation, Leanne & Winston Newman Charitable Trust, Lillie Johnson Charitable Trust, Mactaggart Third Fund, Paragon UK (Bristol), Quilter Cheviot (Bristol), Squire Patton Boggs Charitable Trust, Taylor Maxwell Employee Benefit Trust, The Annett Trust, The Edward Cadbury Charitable Trust, The Elizabeth and Prince Zaiger Trust, The Gilander Foundation, The Hospital Saturday Fund, The Walter Guinness Charitable Trust, The William Allen Young Charitable Trust and Westfield Health Charitable Trust.

Financial Sustainability

Following the financial challenges of 2022, we embarked on a five-year financial recovery plan designed to restore stability and build long-term sustainability. We have just completed the third year of that plan.

Year one of the plan (the 2022/23 financial year) delivered a better-than-expected outcome, thanks in part to a combination of one-off legacies, the success of our Emergency Appeal, and significant growth in our hospitality income. These factors resulted in a net surplus of £94,734—an encouraging early step in our recovery journey.

Year two of the plan (2023/24), we concluded the year with a net deficit of £336,310. This was primarily driven by underperformance in legacy income, coupled with slower-than-anticipated momentum in our wider fundraising activity. In addition, while hospitality income remained strong, it plateaued after the significant growth seen in the previous year and therefore did not offset shortfalls in other areas.

In the current financial year (2024/25), momentum in the plan has been regained and a surplus of £212,836 was achieved. Raising income continues to remain challenging but costs have been well managed to mitigate that.

The five-year plan continues to provide a strong framework for financial decision-making, and we remain committed to disciplined financial management, strategic income diversification, and sustainable growth across all areas of the charity.

Securing our future

As we move into the next phase of our work, Securing the Future continues to provide a clear and disciplined framework for decision-making. The year under review has been one of stabilisation and renewed momentum, and the Trustees are confident that the foundations now in place allow the charity to look ahead with purpose and realism.

Our priority remains to reach more people, and more diverse people, earlier in their cancer journey , ensuring that support is accessible, timely and responsive to need. We will continue to balance online delivery—which has become a vital route for many—with a growing in-person offer at Ham Green House, where demand for face-to-face connection and personalised support continues to increase. Alongside this, our integrative cancer care partnership with Genesis Care will remain an important access point for people during active treatment, extending the reach of our whole-person approach.

We will focus our resources on support that delivers the greatest gains in quality of life , guided by evidence and by what people using our services tell us matters most. The charity will continue to strengthen how it measures, understands, and communicates impact, using outcomes data to inform service development and to clearly demonstrate the difference our work makes.

Key challenges ahead

The Trustees recognise that the period ahead will continue to present significant challenges , both for Penny Brohn Cancer Care and for the wider voluntary sector.

8

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

• Financial sustainability remains a central challenge for the sector as a whole; however progress has been made through the financial recovery plan and free reserves are now above the charity’s policy target. Income generation continues to be affected by economic uncertainty, variability in legacy income, and a competitive fundraising environment so continued diversification of income and careful financial stewardship will therefore remain essential.

• Cost pressures are expected to persist, particularly in relation to staffing, energy and operational costs. Managing these pressures while protecting service quality and staff wellbeing will require ongoing scrutiny, prioritisation and efficiency.

• Balancing demand with capacity will remain a key operational challenge. Demand for services continues to grow, and the charity will need to ensure that expansion is carefully paced, aligned to resources, and supported by a skilled workforce and strong clinical governance.

These challenges are actively monitored through the Board’s governance and risk management processes, and the Trustees remain committed to addressing them in a way that protects the charity’s mission, values and long-term resilience.

Looking ahead, the Trustees believe that Penny Brohn Cancer Care is better positioned than in recent years: clearer in its strategic intent, more stable operationally, and grounded in evidence of impact. With continued focus, partnership and support, we will build on this platform to help more people live as well as possible with and beyond cancer.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Penny Brohn Cancer Care is a registered charity trading as Penny Brohn UK and is also legally constituted as a company limited by guarantee. Established on 17 May 1982, the charity is governed by its Memorandum and Articles of Association, which define its purpose, structure, and operational framework.

Governance

Penny Brohn Cancer Care is overseen by a Board of Trustees, whose primary role is to define the charity’s vision, strategy, and objectives in alignment with its charitable purpose. The Board is responsible for ensuring that the charity’s financial resources are managed effectively and that all activities are conducted in a manner consistent with its mission. In 2025, the Board convened four times in person and once remotely to review progress and guide the organisation.

To maintain comprehensive oversight, the Board operates through five dedicated sub-committees, each focusing on a core aspect of the charity: Finance & Audit, Services, People, Culture & Inclusion, Fundraising & Marketing, and Commercial. These committees meet remotely, ensuring agile governance. In 2025, the Finance & Audit Committee met five times; the Services Committee, Fundraising & Marketing Committee, and Commercial Committee and the People, Culture & Inclusion Committee each met four times.

Trustee Appointment, Induction, and Training

Trustees are appointed based on the skills and expertise required for strong governance at Penny Brohn Cancer Care. A formal recruitment process is in place to identify suitable candidates, ensuring they align with the organisation’s needs and values. Once appointed, each Trustee undergoes a comprehensive induction and training process, tailored to their individual background and experience. This includes access to key documents, a guided tour of the National Centre, introductions to the Chair, Executive Team, and key staff, and an overview of the roles, responsibilities, and obligations of being a Trustee.

9

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

Trustees are encouraged to participate in internal and external development opportunities that enhance their ability to fulfil their governance role effectively. A Trustee’s term of office lasts three years, with the option to serve up to three consecutive terms. Extensions beyond this period are only granted in exceptional circumstances. All Trustees volunteer their time and receive no financial compensation or benefits from the charity. They are required to declare any conflicts of interest and must withdraw from decision-making where conflicts arise. Details of any expenses reclaimed or related party transactions can be found in note 8 and 25 of the financial statements.

Key Management

The Board entrusts the day-to-day management of Penny Brohn Cancer Care to the Chief Executive Officer (CEO), who is supported by a Senior Leadership Team. This team meets weekly to oversee operations and actively participates in Trustee sub-committee meetings related to their areas of responsibility.

Public Benefit

The Trustees ensure that Penny Brohn Cancer Care continues to deliver meaningful public benefit in line with its mission and objectives. In doing so, they adhere to the Charity Commission’s guidance on Public Benefit under the Charities Act 2011. This commitment ensures that all activities are focused on supporting those affected by cancer in the most effective and impactful ways possible.

Our Charitable Purpose

As outlined in the Articles of Association, Penny Brohn Cancer Care’s charitable purpose is to advance health and well-being, as well as to alleviate sickness and distress, with a particular focus on supporting those affected by cancer. The Trustees retain discretion over how these objectives are best achieved, ensuring the charity remains adaptable to emerging needs.

Pay Policy

The CEO’s remuneration follows the same structured framework as that used for all employees and is governed by the Executive Pay Policy. This policy is regularly reviewed by the People, Culture & Inclusion sub-committee, with oversight from the Trustee Board, to ensure fairness and alignment with sector standards.

Trading Subsidiary

To support its charitable work, Penny Brohn Cancer Care operates a wholly owned trading subsidiary, PB UK Commercial Ltd. This subsidiary generates revenue through commercial activities and donates all taxable profits via Gift Aid to the charity. PB UK Commercial Ltd is managed by a Board of Directors, which included two Trustees during the reporting year. The charity retains full ownership of the subsidiary’s share capital.

Risk Management

The Trustees have implemented a comprehensive risk management strategy to safeguard the charity’s operations and long-term sustainability. This includes:

10

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

By maintaining robust governance and proactive risk management, Penny Brohn Cancer Care continues to strengthen its resilience, ensuring it can provide essential support to people living with cancer now and in the future.

Strategic Risk Register

Penny Brohn Cancer Care recognises that strategic risks have the potential to significantly impact the achievement of our core mission. These risks may arise from internal factors, such as financial sustainability or regulatory compliance, or be driven by external events that are beyond our control but require a proactive response.

To manage these risks effectively, we maintain a Strategic Risk Register, which enables us to identify, assess, and mitigate key threats to our organisation. This structured approach ensures that we remain resilient, adaptable, and well-prepared to navigate challenges while continuing to provide high-quality support to those affected by cancer.

The key strategic risks identified for the organisation are:

Each of these risks is actively monitored and managed through robust governance structures, including oversight from relevant sub-committees and continuous evaluation of our financial, operational, and strategic positioning. By maintaining a dynamic and responsive approach to risk management, Penny Brohn Cancer Care ensures that we remain well-equipped to fulfil our mission while safeguarding the long-term sustainability of the charity.

Fundraising Standards

At Penny Brohn Cancer Care, our work is made possible through the generosity and commitment of our supporters. We take this responsibility seriously and are dedicated to ensuring that all fundraising activities are conducted ethically, transparently, and in line with best practice.

We employ a diverse range of fundraising approaches to maximise our impact and support our vision. These include direct mail and email campaigns, community and sponsored challenge events, and dedicated fundraising events. We also welcome legacy and in-memoriam donations, work closely with grant-giving trusts and foundations, and cultivate corporate partnerships to further our mission.

As a registered member of the Fundraising Regulator, Penny Brohn Cancer Care adheres to the Code of Fundraising Practice, ensuring that our activities meet the highest standards of integrity and

11

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

accountability. Additionally, we are proud to be an organisational member of the Institute of Fundraising, further demonstrating our commitment to excellence in fundraising.

All fundraising efforts are managed directly by our in-house team, and we do not engage third-party professional fundraisers or commercial participators to solicit funds on our behalf. One exception is our fundraising lottery, which is licensed by North Somerset Council and administered externally through Unity Lottery (Sterling Management Centre Limited), a licensed External Lottery Manager (ELM) regulated by the Gambling Commission. We ensure full compliance with all relevant codes and laws, including providing guidance on responsible gambling, self-exclusion options, and support for vulnerable individuals.

Respect for our supporters is at the heart of our approach. We are committed to ensuring that no one is subjected to undue pressure or persistent requests for donations. Every communication includes an option to unsubscribe or opt out, allowing individuals to engage with us in a way that feels right for them. Above all, we prioritise compassion and ethical engagement, particularly when working with vulnerable individuals.

We are pleased to report that in the past year, we have received no complaints regarding our fundraising activities, reflecting our dedication to maintaining the highest standards of trust and accountability.

Staff

In 2025 the charity implemented several staff and role changes. Two roles were combined to appoint a new Head of Fundraising and Communications, enabling the Fundraising and Communications teams to come together, creating a new and robust structure for the future. In addition to this, a further two roles were combined within the Services team and the new role of Psychological and Emotional Support lead was successfully recruited with a view to reviewing the client service offering within this area.

Overall, the headcount for the year remained static with 61 core staff, 37 regular zero-hour staff and 12 casual staff employed by the end of 2025.

The zero-hour work force continues to flexibly support the growing Hospitality part of the business at the national centre as well as the Treatment Support team within GenesisCare.

During the summer, two A level students were offered the opportunity of a one week work experience placement at the national centre. Following positive feedback at the end of the week, this will be repeated for a further two students in 2026 and beyond. The charity is pleased to be able to offer these opportunities to support our local schools and young people.

Volunteers

Penny Brohn Care Care continues to value the support of its volunteer workforce. In 2025 volunteers gave on average 500 hours per month leading to an overall 20% increase in hours from the year before. The volunteer Garden team continue to be the largest volunteer group and the Services team have continued to welcome new volunteers looking to actively support clients with the Wellbeing Day buddies being a popular role.

Clinical Governance

Ensuring the safety and quality of our client-facing services remains a top priority at Penny Brohn Cancer Care. Our commitment to clinical governance spans all aspects of service delivery, including face-to-face, virtual, remote, and online resources. Through a robust quality assurance framework, we continuously evaluate and refine our services to uphold the highest standards of safety, care, fairness, leadership, and responsiveness.

12

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

Our clinical governance framework is designed to safeguard the well-being of our clients, ensuring that every individual accessing our support receives the best and safest care possible. By maintaining a structured and proactive approach, we remain dedicated to delivering services that are not only effective but also aligned with the evolving needs of those we support.

FINANCIAL REVIEW

Statement of Financial Activities (SoFA)

In 2025, the Group generated £2,585m in unrestricted income (2024: £2.159m) and £228,208 in restricted income (2024: £269,309), leading to a total income of £2.813m (2024: £2.429m).

Our principal sources of income for the year were:

Income Source 2025(£’000) 2024(£’000)
Trusts and Grants 328 248
Services and Strategic
Partnerships
895 894
Donations, Community
and Corporate Giving
494 578
Legacies 292 53
Retail & Hospitality 804 656
Total 2,813 2,429

Despite the continuing economic pressures, the charity has made a small surplus for the year. Our longstanding partnership with GenesisCare has remained a reliable contributor to our income base.

We were again grateful for the support of charitable trusts and foundations, including a generous contribution of £134,523 from Walk the Walk, an enduring funder whose backing has enabled us to deliver our ‘Feel Better’ package of care and provide practical support for people preparing to undergo chemo and radiotherapy and offset the side effects of their treatment.

Balance Sheet

The Group’s net assets increased by £129,378. Current assets increased by £254,209 and creditors due within one year decreased by £60,125. The £200k credit banking facility drawn down last year was converted to a 5 year loan. The mortgage on the National Centre continued to be repaid in line with expectations, resulting in a further reduction in long-term liabilities.

Free reserves increased by £447k, bringing the year-end balance to £563k, while designated funds, including the value of land, remained static at £4.714m.

PB UK Commercial Ltd

Our trading subsidiary, PB UK Commercial Ltd, continued to operate key income-generating activities such as room hire and hospitality services at the National Centre, along with retail through The Hub and our online shop. In 2025, the subsidiary delivered a profit of £27k.

Reserves Policy

13

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

Going Concern

The Finance and Audit Committee continues to monitor financial performance closely, including regular scrutiny of cash flow, income forecasting, and debt obligations.

In light of current reserves, ongoing income diversification, and access to secured borrowing, the Trustees have reasonable confidence in the charity’s ability to continue operating for at least 12 months beyond the date of this report. The going concern basis of accounting has therefore been applied in preparing the 2025 financial statements.

14

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

Statement of trustees’ responsibilities

The trustees (who are also directors of Penny Brohn Cancer Care for the purposes of company law) are responsible for preparing the Trustees’ Report (incorporating the strategic report and directors’ report) and the financial statements in accordance with applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and the group and of the income and expenditure, of the charitable group for that period. In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

Approved by order of the members of the Board of Trustees and signed on their behalf by:

Stephen Rosser

Chair of Trustees

Date: 17[th] July 2026

15

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

Independent auditor’s report to the members of Penny Brohn Cancer Care

Opinion

We have audited the financial statements of Penny Brohn Cancer Care (the “parent charitable company”) for the year ended 30 November 2025 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted out audit in accordance with international Standards in Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If based, on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report the fact.

We have nothing to report in this regard.

16

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the Group’s and the parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

17

PENNY BROHN CANCER CARE ANNUAL REPORT AND ACCOUNTS

Act 2006, taxation legislation and data protection, anti-bribery, employment, pensions, environmental and health and safety legislation; and

Our audit procedures in relation to fraud included but were not limited to:

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of noncompliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any. Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at www.frc.org.uk/auditors/audit-assurance-ethics/auditorsresponsibilities-for-the-audit. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the parent charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the parent charitable company’s members those matters we are required to state in them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the parent charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Joshua Kingston ACA (Senior Statutory Auditor)

For and on behalf of Burton Sweet Limited

Statutory Auditor The Clock Tower 5 Farleigh Court Old Weston Road Flax Bourton Bristol BS48 1UR

Date: ………………….. 2 9 July 2026

18

PENNY BROHN CANCER CARE

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME & EXPENDITURE ACCOUNT) YEAR ENDED 30 NOVEMBER 2025

Note
Income from:
Donations and legacies
2
Charitable activities
3
Other trading activities
4
Investments
Other income
Total income
Expenditure on:
Raising funds
5
Charitable activities
6
Total expenditure
Net gains on investments
Net income/(expenditure) for the year
8
Loss on revaluation of fixed asset
12
Net movement in funds
22
Total funds at end of year
22
Total funds at the start of the year
Unrestricted
Funds
£
885,824
901,187
797,704
762
-
2,585,477
537,125
1,836,817
2,373,942
1,301
212,836
-
212,836
5,071,570
5,284,406
Restricted
Funds
£
228,208
-
-
-
-
228,208
-
311,666
311,666
-
(83,458)
-
(83,458)
159,390
75,932
Total Funds
2025
£
1,114,032
901,187
797,704
762
-
2,813,685
537,125
2,148,483
2,685,608
1,301
129,378
-
129,378
5,230,960
5,360,338
Total Funds
2024
£
868,223
905,450
655,911
440
(1,364)
2,428,660
589,027
2,175,943
2,764,970
-
(336,310)
(376,629)
(712,939)
5,943,899
5,230,960

The Group has no recognised gains or losses other than the results for the year as set out above. All of the activities of the Group are classed as continuing.

See note 11 for the comparative Statement of Financial Activities.

The notes on pages 23 to 39 form part of these financial statements.

19

PENNY BROHN CANCER CARE

THE CHARITY'S STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME & EXPENDITURE ACCOUNT) YEAR ENDED 30 NOVEMBER 2025

Note
Income from:
Donations and legacies
2
Charitable activities
3
Other trading activities
4
Investments
Other income
Total income
Expenditure on:
Raising funds
5
Charitable activities
6
Total expenditure
Net gains on investments
14
Net income/(expenditure) for the year
8
Loss on revaluation of fixed asset
12
Net movement in funds
Total funds at start of year
22
Total funds at end of year
22
Unrestricted
Funds
£
885,824
901,187
720,432
762
-
2,508,205
526,750
1,836,817
2,363,567
1,301
145,939
-
145,939
5,041,470
5,187,409
Restricted
Funds
£
228,208
-
-
-
-
228,208
-
311,666
311,666
-
(83,458)
-
(83,458)
159,390
75,932
Total Funds
2025
£
1,114,032
901,187
720,432
762
-
2,736,413
526,750
2,148,483
2,675,233
1,301
62,481
-
62,481
5,200,860
5,263,341
Total Funds
2024
£
868,223
905,450
585,330
440
(1,364)
2,358,079
559,085
2,175,943
2,735,028
-
(376,949)
(376,629)
(753,578)
5,954,438
5,200,860

The Charity has no recognised gains or losses other than the results for the year as set out above. All of the activities of the Charity are classed as continuing.

See note 11 for the comparative Statement of Financial Activities.

The notes on pages 23 to 39 form part of these financial statements.

20

PENNY BROHN CANCER CARE

BALANCE SHEETS

AS AT 30 NOVEMBER 2025

----- Start of picture text -----
AS AT 30 NOVEMBER 2025 Company number: 01635916
Group Charity Group Charity
2025 2025 2024 2024
Note £ £ £ £
Fixed assets
Intangible assets 12 1,283 1,283 - -
Tangible assets 13 5,754,562 5,754,562 5,837,650 5,837,650
Investments 14 7,431 7,432 6,129 6,131
5,763,276 5,763,277 5,843,779 5,843,781
Current assets
Stock 15 6,779 - 7,528 -
Debtors 16 442,377 417,886 316,850 441,602
Cash at bank and in hand 538,476 501,416 409,045 252,317
987,632 919,302 733,423 693,919
Liabilities
Creditors : amounts falling due within one year 17 (418,203) (446,871) (478,328) (468,926)
Net current assets 569,429 472,431 255,095 224,993
Total assets less current liabilities 6,332,705 6,235,708 6,098,874 6,068,774
Creditors : amounts falling due after more than one year 18 (972,367) (972,367) (867,914) (867,914)
Net assets 5,360,338 5,263,341 5,230,960 5,200,860
FUNDS
Restricted funds 23 75,932 75,932 159,390 159,390
Unrestricted funds
General funds 23 570,193 473,196 121,627 91,527
Designated funds (including revaluation reserve of 23 4,714,213 4,714,213 4,949,943 4,949,943
£4,281,160 (2024: £4,337,332)
Total unrestricted funds 5,284,406 5,187,409 5,071,570 5,041,470
Total funds 5,360,338 5,263,341 5,230,960 5,200,860
----- End of picture text -----

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

These financial statements were approved by the Trustees on 17th July 2026 and are signed on their behalf by:

…........................................................

Stephen Rosser Chair of Trustees

The notes on pages 23 to 39 form part of these financial statements.

21

PENNY BROHN CANCER CARE

CONSOLIDATED STATEMENT OF CASH FLOWS

YEAR ENDED 30 NOVEMBER 2025

Note
Net cash inflow/(outflow) from operating activities
19
Non-operational cash flows:
Investing activities
Payments for tangible fixed assets
Payments for intangible assets
Proceeds from disposal of fixed assets
Investment income
Financing activities
Loan repayments
Loan advancement
Net cash inflow/(outflow) for the year
20
2025
£
234,414
(16,440)
(1,480)
-
762
(17,158)
(87,825)
-
(87,825)
129,431
2024
£
(281,215)
(49,242)
(16)
30,000
440
(18,818)
(71,684)
200,000
128,316
(171,717)

Cashflow Restrictions

Charity law prohibits the use of net cash inflows on any endowed or other restricted fund to offset net cash outflows on any fund outside its own objects, except on special authority. In practice, this restriction has not had any effect on cash flows for the year.

The notes on pages 23 to 39 form part of these financial statements.

22

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

1 Accounting policies

Accounting convention

The financial statements have been prepared in accordance with the historical cost convention (except where otherwise stated in the accounting policy note) and in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019, and the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), and the Companies Act 2006.

The charity is a public benefit entity as defined under FRS102.

Going concern

The Charity’s forecasts and projections show that the Charity expects to operate within the level of its current debt facility. As detailed in the annual report, the Charity seeks to increase income from fundraising to enable more people to access free support to help them live well with cancer, and allow us to influence the healthcare agenda.

The Finance and Audit Committee regularly review various relevant reports from the Charity, including forecast cash flow scenarios, to attest positively to the Charity’s going concern status. This review is shared with the full Trustee Board at each Trustee meeting.

The Charity has two committed working capital loan facilities. It plans to continue to hold these term debt facilities, secured on the National Centre, that are used to bridge timing gaps in revenue raising. The Charity received a £50,000 Bounce Back loan in December 2020, this loan has a full (100%) government-backed guarantee against the balance of the facility, repayments of this loan commenced in December 2021. In April 2025 the charity converted a £200k Revolving Credit Facility that was in place at the end of the 2024 financial year into a fiveyear term loan. In addition to these, the Charity holds a 10 year mortgage which expires in 2029.

The Trustees have a structured approach to the financial strategy of the Charity, which included the 5 year plan reviewed by Trustees annually from which the 12 month budget and cashflow forecast is prepared. Quarterly forecasts are also prepared. Trustees review and monitor the budgets and cashflows at each Trustees meeting, interrogating variances. This continuous monitoring and control ensure the Trustees are able to properly review the Charity’s going concern status and its financial viability, The Trustees review the Charity’s forecast and projections at each Board meeting and have a reasonable expectation that the Charity has adequate resources to continue in operational existence for a period of at least 12 months following the date of approval of these financial statements. The Group therefore continues to adopt the going concern basis for preparing its consolidated financial statements.

Basis of consolidation

The Consolidated Statement of Financial Activities (SOFA), Consolidated Balance Sheet and Consolidated Cash Flow Statement consolidate the financial statements of the Charity and its subsidiary, PB UK Commercial Ltd. The results of the subsidiary are consolidated on a line by line basis.

Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, which are described in this note, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects the current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets and liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year. The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the presentation of the financial statements are outlined in the following paragraphs.

23

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

1 Accounting policies (continued)

Income

Income from donations is included in income when these are receivable, except as follows:

I. When donors specify that donations given to the charity must be used in future accounting periods, the income is deferred until those periods;

II. When donors impose conditions which have to be fulfilled before the charity becomes entitled to use such income, the income is deferred until the pre-conditions have been met.

Legacies are included on a receivable basis where the charity is entitled to the income, it can be measured reliably and receipt is probable. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is not included in income but is treated as a contingent asset and disclosed if material.

Investment income is included on a receivable basis.

Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of the resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure includes attributable VAT which cannot be recovered.

Raising funds

Raising funds expenditure includes those costs incurred in seeking voluntary contributions, costs of goods sold and other costs which include the costs of running and participating in fundraising events and collections and cost of goods purchased for resale.

Charitable Activities

Expenditure on charitable activities comprises those costs incurred by the Charity in the delivery of its activities and services. It includes both costs that can be allocated directly to this activity and those costs of an indirect nature necessary to support them.

Support costs and other costs that cannot be directly attributed to activities are allocated on a basis consistent with the use of the resource.

Governance costs

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include the audit fees and costs linked to the strategic management of the charity. Governance costs are included within support costs.

Pension costs and other post-retirement benefits

The charity contributes to defined contribution pension schemes. Contributions payable to the charity's pension schemes are charged to the Statement of Financial Activities in the period to which they relate.

Intangible assets

Intangible assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost less accumulated amortisation and impairment. Amortisation is calculated so as to write off the cost of an asset, less its estimated ultimate residual value, over the useful life of that asset as follows:

Computer software

24

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

1 Accounting policies (continued)

Tangible fixed assets

Freehold buildings are included at valuation based on open market valuation. Valuations are performed every five years. All other tangible fixed assets are included at cost less accumulated depreciation. Tangible fixed assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

The Trustees of the charity carry out an annual impairment review of the properties.

Depreciation is calculated to write off the cost or valuation of tangible fixed assets, less its estimated ultimate residual value, over the useful life of that asset as follows:

Freehold property - 2% straight line on buildings, no depreciation charged on land Long-term leasehold property - based upon the length of the lease Fixtures and fittings - 5 to 10 years straight line basis Computer equipment - 3 to 5 years straight line basis

Investment property

The land and buildings that constitute the National Centre of Penny Brohn Cancer Care form a mixed use property where elements of the property are used for charitable purposes and elements are let or used commercially. As the investment property elements are not separable and the fair value cannot be measured reliably, the entire property is accounted for as property within tangible fixed assets.

Fixed asset investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and loss, whether realised or unrealised are combined and recognised as a gain or loss on investments in the SOFA.

Investments in subsidiaries and associates are included at cost less impairment at 30 November in the charity's accounts.

Stock

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

Donated items are not valued in stock and are recognised in income only when sold.

Cash and cash equivalents

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised when the charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets, which include trade and other receivables and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

Basic financial liabilities, including trade and other payables, and loans from group undertakings, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

25

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

1 Accounting policies (continued)

Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. The costs of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

2 Income from donations and legacies

Group & Charity

General donations
Donations from regular givers
Legacies received
Legacies accrued but not received
Total for Group & Charity
Prior year
General donations
Donations from regular givers
Legacies received
Legacies accrued but not received
Total for Group & Charity
Income from charitable activities
Group & Charity
Service generated income from partnerships
Other service generated income
Catering income
Unrestricted
Funds
£
879,069
15,368
6,750
901,187
Unrestricted
Funds
£
518,843
75,090
41,583
250,308
885,824
Unrestricted
Funds
£
469,124
76,514
11,276
42,000
598,914
Restricted
Funds
£
-
-
-
-
Restricted
Funds
£
228,208
-
-
-
228,208
Restricted
Funds
£
269,309
-
-
-
269,309
Total Funds
2025
£
879,069
15,368
6,750
901,187
Total Funds
2025
£
747,051
75,090
41,583
250,308
1,114,032
Total Funds
2024
£
738,433
76,514
11,276
42,000
868,223
Total Funds
2024
£
894,303
112
11,035
905,450

3 Income from charitable activities

All income received for charitable activities in the prior year was unrestricted.

26

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

4 Income from other trading activities

Trading income:
Facilities income
The Hub
PB UK Commercial - management charges
Total Charity
PB UK Commercial income
Inter-group activity
Total Group
Unrestricted
Funds
£
117,769
121,713
480,950
720,432
558,222
(480,950)
797,704
Restricted
Funds
£
-
-
-
-
-
-
-
Total Funds
2025
£
117,769
121,713
480,950
720,432
558,222
(480,950)
797,704
Total Funds
2024
£
88,152
108,372
388,806
585,330
459,387
(388,806)
655,911

All income received for other trading activities in the prior year was unrestricted.

5 Expenditure on raising funds

Current year
The Hub
Fundraising support costs (note 7)
Total Charity
PB UK Commercial - management charges
PB UK Commercial - other trading expenses
Inter-group activity
Total Group
Total Funds
2025
£
148,796
377,954
526,750
480,950
10,375
(480,950)
537,125
Total Funds
2024
£
128,924
430,161
559,085
388,806
29,942
(388,806)
589,027

6 Expenditure on charitable activities

Group & Charity
Online services
In-person/group services
One to one services
Partnerships
Hospitality
Group & charity totals
Direct
Costs
£
124,897
45,486
160,906
714,071
381,542
1,426,902
Support
Costs
(Note 7)
£
87,862
31,998
113,193
220,125
268,403
721,581
Total Funds
2025
£
212,759
77,484
274,099
934,196
649,945
2,148,483

27

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

6 Expenditure on charitable activities (continued)

Prior year
Online services
In person/ group services
One to one services
Partnerships
Hospitality
Group & charity totals
Direct
Costs
£
93,452
57,311
266,844
701,616
330,314
1,449,537
Support
Costs
(Note 7)
£
64,934
39,822
185,415
206,719
229,516
726,406
Total Funds
2024
£
158,386
97,133
452,259
908,335
559,830
2,175,943

7 Support costs

Support costs are allocated between raising funds and charitable activities on the basis of staff time.

Support costs, included in notes 5 & 6, are as follows:

Current year
Staff costs
Other costs
Office costs
Building costs
Finance costs
Governance costs
Group & charity totals
Prior year
Staff costs
Other costs
Office costs
Building costs
Finance costs
Governance costs
Group & charity totals
Fundraising
and
publicity
£
249,170
52,298
22,379
41,815
6,978
5,314
377,954
Fundraising
and
publicity
£
277,813
69,062
21,972
49,689
6,514
5,111
430,161
Charitable
Activities
£
207,030
-
150,287
281,714
46,861
35,689
721,581
Charitable
Activities
£
224,691
-
131,637
299,326
39,963
30,789
726,406
Total
2025
£
456,200
52,298
172,666
323,529
53,839
41,003
1,099,535
Total
2024
£
502,504
69,062
153,609
349,015
46,477
35,900
1,156,567

8 Net income/(expenditure) for the year

This is stated after charging:
Auditor's remuneration
- for statutory audit services
- for accounts preparation
Trustees' remuneration
Trustees' travel, meeting and training expenses - None (2024: None)
Amortisation
Depreciation
2025
2024
£
£
14,500
13,060
4,480
4,090
-
-
-
-
197
11,517
98,628
111,896
Group
2025
2024
£
£
14,500
9,460
2,700
2,475
-
-
-
-
197
11,517
98,628
111,896
Charity

Donations from Trustees and related parties amounted to £Nil (2024: £734).

28

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

9 Staff costs and numbers

The aggregate payroll costs were:
2025
2024
£
£
Wages & salaries
1,676,183
1,735,274
Social security costs
164,586
134,756
Pension contributions
81,820
81,338
1,922,589
1,951,368
The average weekly number of employees (including senior management/leadership team) during the year w
2025
2024
£
£
Core staff
61
63
Regular zero hours staff
37
30
Casual staff
12
16
110
109
The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 w
2025
2024
£
£
£70,000 - £79,999
1
1
Group
Group
Group
2025
2024
£
£
1,676,183
1,735,274
164,586
134,756
81,820
81,338
1,922,589
1,951,368
as:
2025
2024
£
£
61
63
37
30
12
16
110
109
as:
2025
2024
£
£
1
1
Charity
Charity
Charity

Key management personnel

The total employee benefits of the key management personnel for the year was £87,881 (2024: £86,966).

10 Taxation

The charity is exempt from corporation tax on its charitable activities.

29

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

11 Statement of Financial Activities comparative figures

Group
For the year ended 30 November 2024
Income from:
Donations and legacies
Charitable activities
Other trading activities
Investments
Other income
Total income
Expenditure on:
Raising funds
Charitable activities
Total expenditure
Net income/(expenditure) for the year
Loss on revaluation of fixed asset
Net movement between funds
Total funds at start of year
Total funds at end of year
Charity
For the year ended 30 November 2024
Income from:
Donations and legacies
Charitable activities
Other trading activities
Investments
Other income
Total income
Expenditure on:
Raising funds
Charitable activities
Total expenditure
Net income/(expenditure) for the year
Loss on revaluation of fixed asset
Net movement between funds
Total funds at start of year
Total funds at end of year
Unrestricted
Funds
£
598,914
905,450
655,911
440
(1,364)
2,159,351
589,027
1,821,694
2,410,721
(251,370)
(376,629)
(627,999)
5,699,569
5,071,570
Unrestricted
Funds
£
598,914
905,450
585,330
440
(1,364)
2,088,770
559,085
1,821,694
2,380,779
(292,009)
(376,629)
(668,638)
5,710,108
5,041,470
Restricted
Funds
£
269,309
-
-
-
-
269,309
-
354,249
354,249
(84,940)
-
(84,940)
244,330
159,390
Restricted
Funds
£
269,309
-
-
-
-
269,309
-
354,249
354,249
(84,940)
-
(84,940)
244,330
159,390
Total Funds
2024
£
868,223
905,450
655,911
440
(1,364)
2,428,660
589,027
2,175,943
2,764,970
(336,310)
(376,629)
(712,939)
5,943,899
5,230,960
Total Funds
2024
£
868,223
905,450
585,330
440
(1,364)
2,358,079
559,085
2,175,943
2,735,028
(376,949)
(376,629)
(753,578)
5,954,438
5,200,860

30

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 30 NOVEMBER 2025

12 Intangible assets
Group and charity
Cost
At 1 December 2024
Additions
Disposals
At 30 November 2025
Amortisation
At 1 December 2024
Charge for the year
Elimination on disposal
At 30 November 2025
Net Book Value
At 30 November 2025
At 30 November 2024
13 Tangible fixed assets
Group and charity
Cost or valuation
At 1 December 2024
Additions
Disposals
At 30 November 2025
Depreciation
At 1 December 2024
Charge for the year
Eliminated on disposal
At 30 November 2025
Net book value
At 30 November 2025
At 30 November 2024
Freehold
property
£
5,640,000
-
-
5,640,000
-
56,172
-
56,172
5,583,828
5,640,000
Long-term
leasehold
property
£
120,489
1,610
-
122,099
59,222
12,123
-
71,345
50,754
61,267
Fixtures and
fittings
£
160,025
11,384
(630)
170,779
51,046
20,812
(320)
71,538
99,241
108,979
Computer
Software
£
86,376
1,480
(86,376)
1,480
86,376
197
(86,376)
197
1,283
-
Computer
equipment
£
64,639
3,446
(4,472)
63,613
37,235
9,521
(3,882)
42,874
20,739
27,404
Total
£
86,376
1,480
(86,376)
1,480
86,376
197
(86,376)
197
1,283
-
Total
£
5,985,153
16,440
(5,102)
5,996,491
147,503
98,628
(4,202)
241,929
5,754,562
5,837,650

It is Penny Brohn Cancer Care's policy to revalue freehold property every 5 years. The freehold property was revalued in May 2025 by Lambert Smith Hampton, a firm of valuers external to the Charity. The property's open market value was considered to be £5,640,000 in accordance with the RICS valuation model .

The historical cost of the revalued freehold property assets amounts to £1,302,668 (2024: £1,302,668).

31

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

14 Fixed asset investments
Listed investments
At 1 December 2024
Unrealised gain/ (loss)
Unlisted investments
Investment in subsidiary
Shares in group undertakings and participating interests:
Cost
At 1 December 2024 and at 30 November 2025
Details of undertakings:
Country of
Company name
incorporation
Holding
PB UK Commercial Ltd
England and Wales
Ordinary
Principal activities
Other retail sale of new goods in specialised stores
Other retail sale not in stores, stalls or markets
Other accommodation
PB UK Commercial Ltd
Turnover
Cost of sales
Gross profit
Administrative expenses
Operating profit
Interest payable and similar charges
Profit before taxation
Tax charge for the year
Profit for the period
Retained earnings brought forward
Retained earnings carried forward
2025
2024
£
£
6,130
6,129
1,301
-
-
-
7,431
6,129
2025
2024
100%
100%
Proportion of voting rights
and shares held
Group
2025
2024
£
£
6,130
6,129
1,301
-
1
2
7,432
6,131
Subsidiary
Undertakings
Total
£
£
1
1
Year ended
Year ended
30 Nov 2025
30 Nov 2024
£
£
558,222
459,387
(487,911)
(403,765)
70,311
55,622
(3,416)
(14,983)
66,895
40,639
-
-
66,895
40,639
-
-
66,895
40,639
30,102
(10,537)
96,997
30,102
Charity

For the year ended 30 November 2025 PB UK Commercial Ltd was entitled to exemption from the audit of its individual accounts under s479A of the Companies Act 2006 relating to subsidiary companies.

32

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

15 Stock

Finished goods and goods for resale
16 Debtors
Trade debtors
Amounts owed by group undertakings
Other debtors
Prepayments and accrued income
17 Creditors: amounts falling due within one year
Bank loans
Other loans
Trade creditors
Amounts owed by group undertakings
Other taxation and social security
Other creditors
Accruals and deferred income
2025
2024
£
£
6,779
7,528
2025
2024
£
£
105,121
96,433
-
-
-
20,370
337,256
200,047
442,377
316,850
2025
2024
£
£
70,134
31,160
10,484
210,225
81,371
85,334
-
-
95,030
75,455
25,033
22,347
136,151
53,807
418,203
478,328
Group
Group
Group
2025
2024
£
£
-
-
2025
2024
£
£
80,630
87,960
-
133,225
-
20,370
337,256
200,047
417,886
441,602
2025
2024
£
£
70,134
31,160
10,484
210,225
80,559
84,784
32,070
-
95,013
75,455
24,283
22,047
134,328
45,255
446,871
468,926
Charity
Charity
Charity

Loan facilities at the year end are with NatWest Bank and Triodos Bank, secured on the freehold property of the Charity.

Deferred income
At 1 December 2024
Amounts released from previous periods
Resources deferred in the period
At 30 November 2025
Creditors: amounts falling due after one year
Bank loans
Other loans
2025
2024
£
£
20,716
10,597
(20,716)
(10,597)
95,155
20,716
95,155
20,716
2025
2024
£
£
971,498
856,547
869
11,367
972,367
867,914
Group
Group
2025
2024
£
£
20,716
10,597
(20,716)
(10,597)
95,155
20,716
95,155
20,716
2025
2024
£
£
971,498
856,547
869
11,367
972,367
867,914
Charity
Charity

18 Creditors: amounts falling due after one year

Loan facilities at the year end are with NatWest Bank and Triodos Bank, secured on the freehold property of the Charity.

33

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

19 Reconciliation of net movement in funds to net cash inflow from operating activities

Group
Statement of Financial Activities: Net movement in funds
Loss on investments
Loan interest
Investment income
Loss on disposal of fixed asset
Amortisation
Depreciation
Increase in operational creditors: current liabilities
Decrease in operational debtors
Decrease in stock
Net cash inflow/(outflow) from operating activities
2025
£
129,378
(1,302)
31,510
(762)
901
197
98,628
100,642
(125,527)
749
234,414
2024
£
(336,310)
-
31,596
(440)
5,268
11,517
111,896
(45,237)
(64,445)
4,940
(281,215)

20 Analysis of changes in cash during the year

Cash at bank and in hand
Cash at bank and in hand
Analysis of changes in net debt
Current year
Cash at bank and in hand
Debt due within one year
Debt due after more than one year
Total
Prior year
Cash at bank and in hand
Debt due within one year
Debt due after more than one year
Total
At 1 Dec
2024
£
409,045
(241,385)
(867,914)
(700,254)
At 1 Dec
2023
£
580,762
(40,087)
(909,300)
(368,625)
Operating
cash flows
£
234,414
-
-
234,414
Operating
cash flows
£
(281,215)
-
-
(281,215)
2025
£
538,476
2024
£
409,045
Investing
cash flows
£
(17,158)
-
-
(17,158)
Investing
cash flows
£
(18,818)
-
-
(18,818)
2024
£
409,045
2023
£
580,762
Financing
cash flows
£
(87,825)
160,767
(104,453)
(31,511)
Financing
cash flows
£
128,316
(201,298)
41,386
(31,596)
Change
£
129,431
Change
£
(171,717)
At 30 Nov
2025
£
538,476
(80,618)
(972,367)
(514,509)
At 30 Nov
2024
£
409,045
(241,385)
(867,914)
(700,254)

21 Analysis of changes in net debt

34

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

22 Movement in funds

For the year ended 30 November 2025
Restricted funds
Library
Lymphoedema
Nutrition
Penny Brohn on the High Street
Relaxation chairs
Remote Services
Treatment Support
Walk the Walk
Walk the Walk Feel Better Package
Garden Room Roof
Menopause
Residential Retreats & Wellbeing Days
Music & Arts
Nicola Corey Fund
One to One
John James In-person support
Scar Therapy
Unrestricted funds
Designated funds
Capital fund including revaluation reserve
General fund
Total funds Charity
PB UK Commercial Ltd
Inter-entity transactions
Total funds Group
At 1 Dec
2024
£
364
54,062
-
10,035
2,275
3,000
21,960
22,478
16,667
11,064
5,200
3,427
2,400
6,458
-
-
-
159,390
4,949,943
91,527
5,041,470
5,200,860
30,102
(2)
30,100
5,230,960
£
-
-
15,000
-
-
24,000
7,321
134,523
-
-
3,000
2,000
-
1,364
3,000
30,000
8,000
228,208
-
2,509,506
2,509,506
2,737,714
558,222
(480,950)
77,272
2,814,986
Income and
gains
£
-
(54,062)
(13,750)
(10,035)
-
(25,000)
(28,781)
(118,996)
(16,667)
-
(8,200)
(5,427)
(2,148)
-
-
(25,000)
(3,600)
(311,666)
(139,472)
(2,224,095)
(2,363,567)
(2,675,233)
(491,325)
480,950
(10,375)
(2,685,608)
Expenditure
and losses
Transfers
£
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
(96,258)
96,258
-
-
(1)
1
-
-
At 30 Nov
2025
£
364
-
1,250
-
2,275
2,000
500
38,005
-
11,064
-
-
252
7,822
3,000
5,000
4,400
75,932
4,714,213
473,196
5,187,409
5,263,341
96,998
(1)
96,997
5,360,338

35

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

22 Movement in funds (continued)

For the year ended 30 November 2024
Restricted funds
Bristol Whole Life Approach in Scotland
Library
Lymphoedema
Nutrition
Other small donations
Penny Brohn on the High Street
Regional donations
Relaxation chairs
Remote Services
Treatment Support
Walk the Walk
Walk the Walk Feel Better Package
Counselling
IT
Garden Room Roof
Menopause
Residential Retreats & Wellbeing Days
Music & Arts
Nicola Corey Fund
Unrestricted funds
Designated funds
Capital fund including revaluation reserve
General fund
Total funds Charity
PB UK Commercial Ltd
Inter-entity transactions
Total funds Group
At 1 Dec
2023
£
11,288
7,293
119,714
-
-
10,035
-
2,275
-
-
93,725
-
-
-
-
-
-
-
-
244,330
5,425,882
284,226
5,710,108
5,954,438
(10,537)
(2)
(10,539)
5,943,899
Income
£
-
-
-
15,000
500
-
3,000
-
61,400
21,960
-
100,000
27,500
1,866
15,000
10,198
3,427
3,000
6,458
269,309
-
2,088,770
2,088,770
2,358,079
459,387
(388,806)
70,581
2,428,660
Expenditure
£
(11,288)
(6,929)
(65,652)
(15,000)
(500)
-
(3,000)
-
(58,400)
-
(71,247)
(83,333)
(27,500)
(1,866)
(3,936)
(4,998)
-
(600)
-
(354,249)
(536,232)
(2,221,176)
(2,757,408)
(3,111,657)
(418,748)
388,806
(29,942)
(3,141,599)
Transfers
£
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
60,293
(60,293)
-
-
-
-
-
-
At 30 Nov
2024
£
-
364
54,062
-
-
10,035
-
2,275
3,000
21,960
22,478
16,667
-
-
11,064
5,200
3,427
2,400
6,458
159,390
4,949,943
91,527
5,041,470
5,200,860
30,102
(2)
30,100
5,230,960

Restricted funds

Library

Following the re-purposing of this grant in 2023, we recruited a part time information and resource officer with the balance of the fund being used to pay for an associate to support the relevant work.

Lymphoedema

A restricted legacy was received to make special facilities available to those clients suffering with Lymphoedema. A lymphoedema workshop takes place each month led by a specialist lymphoedema practitioner.

Nutrition

Gerald Micklem Charitable Trust support the salary costs of our nutrition lead who is responsible for leading and managing the development and delivery of safe, effective, high quality online and in-person nutrition services.

36

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

22 Movement in funds (continued)

Penny Brohn on the High Street

Restricted funds had been received from the Newby Charitable Trust to provide Psychological services at The Hub. This face-to-face service provision was delayed due Covid restrictions.

Relaxation chairs

The relaxation chairs fund is a grant to enable us to upgrade and replace our relaxation chairs.

Remote Services

We continue to provide our programme of online support throughout the year with national reach for people affected by cancer, continually reviewing and adapting our offering. These funds have enabled us to grow this service and embed it as part of our hybrid service model. Grants have been received from The Tim Tiley Bursary Fund, The Helianthus Charitable Trust, The Weinstock Fund, The Hilary Awdry Charitable Trust, The February Foundation and The Medlock Charitable Trust.

Treatment Support

Our online Treatment Support Programme was supported by a grant from The Annet Charitable Trust.

Walk the Walk

A grant was received from Walk the Walk to support and grow our in-person services once again through specialist Wellbeing days and residential retreats.

Walk the Walk Feel Better Package

A grant was received from Walk the Walk to provide a ‘Feel Better’ support package building on of our flagship Treatment Support Programme the funds enabled us to develop, ‘how-to’ resources, online group sessions and specialist wellbeing days.

Garden Room Roof

Donations were made by The Screwfix Foundation and The Will Charitable Trust for repairs to Our Garden Room roof.

Menopause

A grant was received from Gilead to provide specialist menopause sessions, Wellbeing days and resources for those clients experiencing early onset menopause as a result of their cancer treatments.

Residential Retreats & Wellbeing Days

Funds had been received from D’Oyley Carte for a Wellbeing Day taking place in December 2024.

Music & Arts

Funds were received from The Joyce Fletcher Charitable Trust to fund our weekly art sessions and support specialist music and art wellbeing days.

Nicola Corey Fund

Bursaries are available to support parents with a child under the age of 16 to support with the support of childcare, transport or accommodation at our National Centre, where the parent has a cancer diagnosis.

One to One

Funding has been received from The Grace Trust for one-to-one consultations with integrative doctors

John James In-person support

Funds received from The John James Bristol Foundation to support a variety of in-person services offered at the National Centre in Bristol.

Scar Therapy

Grants were received from The Hospital Saturday Fund and Pink Ribbon Foundation to support our scar care programme.

37

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

22 Movement in funds (continued)

Bristol Whole Life Approach in Scotland

The Bristol Whole Life Approach in Scotland was a pilot project to work in partnership with Dumfries House in Ayrshire, giving us the chance to take our Bristol Whole Life Approach to those living with cancer in Scotland.

Other small donations

A donation had been received in 2022 to cover the cost of movement exercise this amount has been fully spent in the prior year. A donation of £500 was received from Quartet Community Foundation restricted to the purchase of kitchen equipment.

Regional donations

A donation was received from J & M Britton Charitable Trust for use in the Bristol area.

Counselling

Support was received from the Newby Trust Ltd to support our counselling programme through the funding of a counsellor who would offers one-to-one counselling, and facilitating an emotional support group. The Albert Hunt Trust and AbbVie UK provided grants to support our oneto-one counselling sessions.

IT

Funds were provided to enable us to purchase three new laptops.

Designated funds

Capital fund and revaluation reserve

The Capital fund represents the net book value of tangible and intangible fixed assets, less loans secured on the relevant assets. The revaluation reserve totals £4,281,160 (2024: £4,337,332) at the year-end.

23 Analysis of net assets between funds

----- Start of picture text -----
Charity Unrestricted
As at 30 November 2025 Restricted Designated General Total
Funds Funds Funds 2025
£ £ £ £
Tangible fixed assets - 5,754,562 - 5,754,562
Intangible fixed assets - 1,283 - 1,283
Fixed asset investments - - 7,432 7,432
Current assets 75,932 - 843,370 919,302
-
Creditors due within one year (70,134) (376,737) (446,871)
-
Creditors over one year (971,498) (869) (972,367)
Total charity 75,932 4,714,213 473,196 5,263,341
As at 30 November 2024 Unrestricted
Restricted Designated General Total
Funds Funds Funds 2024
£ £ £ £
Tangible fixed assets - 5,837,650 - 5,837,650
Fixed asset investments - - 6,131 6,131
Current assets 159,390 - 534,529 693,919
-
Creditors due within one year (31,160) (437,766) (468,926)
-
Creditors over one year (856,547) (11,367) (867,914)
Total charity 159,390 4,949,943 91,527 5,200,860
----- End of picture text -----

38

PENNY BROHN CANCER CARE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 30 NOVEMBER 2025

23 Analysis of net assets between funds ( continued )

Group
As at 30 November 2025
Tangible fixed assets
Intangible fixed assets
Fixed asset investments
Current assets
Creditors due within one year
Creditors over one year
Total Group
As at 30 November 2024
Tangible fixed assets
Intangible fixed assets
Fixed asset investments
Current assets
Creditors due within one year
Creditors over one year
Total Group
Restricted
Funds
£
-
-
-
75,932
-
-
75,932
Restricted
Funds
£
-
-
-
159,390
-
-
159,390
Designated
General
Funds
Funds
£
£
5,754,562
-
1,283
-
-
7,431
-
911,700
(70,134)
(348,069)
(971,498)
(869)
4,714,213
570,193
Designated
General
Funds
Funds
£
£
5,837,650
-
-
-
-
6,129
-
574,033
(31,160)
(447,168)
(856,547)
(11,367)
4,949,943
121,627
Unrestricted
Unrestricted
Total
2025
£
5,754,562
1,283
7,431
987,632
(418,203)
(972,367)
5,360,338
Total
2024
£
5,837,650
-
6,129
733,423
(478,328)
(867,914)
5,230,960

24 Operating lease commitments

At 30 November 2025 the company had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

Amounts payable:
Within one year
Within two and five year
Within over five years
2025
£
42,000
136,500
-
178,500
2024
£
44,094
168,000
10,500
222,594

25 Related parties

Trustees are able to make use of the accommodation at the National Centre when attending on business and usually provide a donation in respect of this. No Trustees were provided any nights accommodation in the year (2024: Nil).

There are no transactions with trustees or other related parties other than those disclosed as required by the SORP elsewhere in the financial statements.

26 Post balance sheet events

Subsequent to the year end, the charity is in the process of entering into an agreement to lease land currently recognised within fixed assets. The land has a net book value of £190,000 at the balance sheet date, and the proposed lease arrangement is for a term of 125 years.

39